Veracyte 過去の業績
過去 基準チェック /56
Veracyteは、平均年間53.1%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間33.8% 22.4%収益成長率で 成長しています。 Veracyteの自己資本利益率は6.5%であり、純利益率は16.2%です。
主要情報
53.12%
収益成長率
54.44%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | 22.36% |
| 株主資本利益率 | 6.55% |
| ネット・マージン | 16.25% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • May 20
VCYT: Mixed Price Revisions Will Pressure Expectations For Future Cash Flow Repricing
Narrative Update Veracyte's updated analyst price target shifts to $37.23 from $38.59, as analysts factor in a slightly higher discount rate, more moderate revenue growth expectations, a higher projected profit margin, and a lower assumed future P/E multiple, informed by recent mixed target revisions and a new bullish initiation. Analyst Commentary Recent research on Veracyte reflects a split view, with some firms turning more constructive while several bearish analysts have trimmed price targets and highlighted execution and valuation risks.分析記事 • May 14
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s ( NASDAQ:VCYT...
ナラティブの更新 • Apr 28
VCYT: Revised Street Views Will Highlight Medium Term Revenue Guidance Story
Analysts now see a modestly lower upside for Veracyte, trimming the consensus price target by a few dollars to around the mid $30s. Recent research reflects a balance between reduced targets from several firms and a newer bullish initiation that emphasizes the company's longer term growth potential.ナラティブの更新 • Apr 14
VCYT: Bullish Coverage And Margin Reset Will Strengthen Prostate Cancer Risk Position
Analysts now see Veracyte's fair value at $53, up from $51. This revision reflects updated assumptions around growth, profitability and valuation multiples informed by recent Street research, including both fresh coverage and revised price targets.
ナラティブの更新 • Mar 31
VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside
Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results.ナラティブの更新 • Mar 17
VCYT: NCCN Risk Stratification Focus Will Support Future Cash Flow Repricing
Analysts have lowered their price target on Veracyte from $43.00 to about $38.59, citing updated assumptions for revenue growth, profit margins and future P/E following recent model revisions. This includes a reduced $37 target from one large Wall Street firm after Q4 results.ナラティブの更新 • Mar 02
VCYT: 2026 Revenue Outlook And Higher Future P/E Will Lift Long-Term Upside
Analysts now set their Veracyte price target at $48.60, compared with $47.50 previously. This reflects updated views on revenue growth, profit margin assumptions and a higher future P/E multiple.ナラティブの更新 • Feb 16
VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role
Analysts have kept their $51.00 price target for Veracyte unchanged, citing updated assumptions that reflect slightly lower discount rates, modestly higher revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Veracyte issued earnings guidance for the fourth quarter of 2025, with expected total revenue between US$138 million and US$140 million, described as 16% to 18% growth for the period.ナラティブの更新 • Feb 02
VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption
Narrative Update on Veracyte Analysts have kept their Veracyte fair value target steady at $43.00, citing updated NCCN prostate cancer guidelines that highlight Decipher’s role in risk stratification and support slightly adjusted assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Recent commentary points to the updated NCCN prostate cancer guidelines as a supportive data point for Veracyte’s Decipher test.ナラティブの更新 • Jan 19
VCYT: NCCN Guideline Support Will Strengthen Prostate Cancer Risk Stratification Role
Analysts have lifted their price target on Veracyte from US$45.00 to US$51.00, citing updated NCCN guidelines that they view as incrementally favorable for the company’s Decipher prostate cancer test and its differentiation based on clinical evidence. Analyst Commentary Bullish analysts are framing the latest NCCN prostate cancer guideline update as a meaningful support for Veracyte’s Decipher test, especially around how it is positioned within risk stratification.Seeking Alpha • Jan 16
Veracyte: Profitable, De-Risked, And Ready To Run
Summary Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration, entry into minimal residual disease, and U.S. re-launch of the Prosigna breast cancer test. VCYT projects 16% revenue growth to $515–$517M in FY25 and >25% adjusted EBITDA margin, signaling sustained profitable execution. A robust digital pathology database and AI-driven bioinformatics platform create significant competitive moats and future product opportunities. Read the full article on Seeking Alphaナラティブの更新 • Jan 05
VCYT: NCCN Guideline Support Will Shape Future Decipher Adoption And Competitive Risks
Analysts have lifted their price target on Veracyte from $28.40 to $43.00, citing updated NCCN prostate cancer guidelines that highlight the Decipher test in key risk stratification tables as support for a higher fair value assumption. Analyst Commentary Analysts point to the updated NCCN V3.2026 prostate cancer guidelines as a supportive data point for Veracyte, highlighting that Decipher is explicitly listed in the principles of risk stratification tables across several key prostate cancer settings.ナラティブの更新 • Dec 15
VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption
Analysts have modestly raised their price target on Veracyte to approximately $47.50 from about $46.30, citing slightly stronger long term growth and profitability expectations, as well as the incremental boost from updated NCCN guidelines that further differentiate the company’s Decipher prostate cancer test. Analyst Commentary Street research characterizes the NCCN guideline update as a net positive for Veracyte, with the Decipher prostate cancer test receiving prominent placement in risk stratification tables across multiple disease stages.ナラティブの更新 • Nov 29
VCYT: New NCCN Guidelines Will Support Continued Market Differentiation
Analysts have raised their price target for Veracyte from $45.30 to $46.30, citing ongoing positive inclusion of the company’s Decipher test in updated clinical guidelines as a contributing factor. Analyst Commentary Analysts have examined the recent updates to the clinical guidelines and their implications for Veracyte’s Decipher test, highlighting both opportunities and potential challenges facing the company.分析記事 • Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Veracyte, Inc. ( NASDAQ:VCYT ) shares have been powering on, with a gain of 27% in the...ナラティブの更新 • Nov 15
VCYT: Expanded Prostate Cancer Guidelines Will Drive Demand Ahead
Veracyte's analyst price target has been raised from $41.10 to $45.30. Analysts cite stronger guidelines support, as well as improved revenue and profit growth expectations, as key drivers.ナラティブの更新 • Nov 01
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.ナラティブの更新 • Oct 18
Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets
Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.分析記事 • Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Veracyte, Inc. ( NASDAQ:VCYT ) is a stock worth...分析記事 • May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
As you might know, Veracyte, Inc. ( NASDAQ:VCYT ) just kicked off its latest quarterly results with some very strong...新しいナラティブ • May 07
Decipher, Afirma And MRD Tests Will Broaden Future Markets
Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.分析記事 • Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Even though Veracyte, Inc. ( NASDAQ:VCYT ) posted strong earnings, investors appeared to be underwhelmed. We have done...分析記事 • Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders that were waiting for something to happen have been dealt a blow with a 26...分析記事 • Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Key Insights Veracyte's estimated fair value is US$65.48 based on 2 Stage Free Cash Flow to Equity Veracyte is...Seeking Alpha • Dec 11
Veracyte: Getting Frothy
Summary Veracyte has seen its stock more than double since early August, driven by strong Q3 results and increased revenue guidance for FY2024. This medical diagnostic firm focused on oncology is executing well, but the stock looks a bit 'frothy' based on some valuation metrics. The analyst community is also somewhat mixed based on the stock's valuation, and there was some notable insider selling following Q3 results. Can the rally continue in Veracyte? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Veracyte, Inc. ( NASDAQ:VCYT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...分析記事 • Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders have had their patience rewarded with a 42% share price jump in the last...分析記事 • Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Shareholders will be ecstatic, with their stake up 39% over the past week following Veracyte, Inc. 's ( NASDAQ:VCYT...分析記事 • Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Key Insights The projected fair value for Veracyte is US$37.52 based on 2 Stage Free Cash Flow to Equity Veracyte's...分析記事 • Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Veracyte, Inc.'s ( NASDAQ:VCYT ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...分析記事 • May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Veracyte, Inc. ( NASDAQ:VCYT ) investors will be delighted, with the company turning in some strong numbers with its...収支内訳
収支内訳
Veracyte の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 542 | 88 | 219 | 80 |
| 31 Dec 25 | 517 | 66 | 226 | 71 |
| 30 Sep 25 | 495 | 30 | 212 | 69 |
| 30 Jun 25 | 479 | 26 | 216 | 71 |
| 31 Mar 25 | 463 | 33 | 212 | 71 |
| 31 Dec 24 | 446 | 24 | 204 | 69 |
| 30 Sep 24 | 425 | -9 | 212 | 69 |
| 30 Jun 24 | 400 | -54 | 200 | 64 |
| 31 Mar 24 | 375 | -68 | 195 | 61 |
| 31 Dec 23 | 361 | -74 | 193 | 57 |
| 30 Sep 23 | 343 | -50 | 186 | 50 |
| 30 Jun 23 | 329 | -29 | 184 | 47 |
| 31 Mar 23 | 311 | -30 | 174 | 53 |
| 31 Dec 22 | 297 | -37 | 171 | 41 |
| 30 Sep 22 | 284 | -43 | 187 | 40 |
| 30 Jun 22 | 268 | -49 | 177 | 37 |
| 31 Mar 22 | 251 | -48 | 171 | 30 |
| 31 Dec 21 | 220 | -76 | 180 | 30 |
| 30 Sep 21 | 187 | -73 | 119 | 24 |
| 30 Jun 21 | 157 | -63 | 105 | 20 |
| 31 Mar 21 | 123 | -65 | 89 | 17 |
| 31 Dec 20 | 117 | -35 | 88 | 17 |
| 30 Sep 20 | 113 | -34 | 86 | 17 |
| 30 Jun 20 | 113 | -31 | 87 | 23 |
| 31 Mar 20 | 122 | -22 | 89 | 11 |
| 31 Dec 19 | 120 | -13 | 83 | 15 |
| 30 Sep 19 | 116 | -8 | 77 | -1 |
| 30 Jun 19 | 109 | -12 | 73 | -8 |
| 31 Mar 19 | 101 | -16 | 67 | 0 |
| 31 Dec 18 | 92 | -23 | 65 | 15 |
| 30 Sep 18 | 86 | -28 | 63 | 15 |
| 30 Jun 18 | 80 | -31 | 61 | 15 |
| 31 Mar 18 | 76 | -32 | 59 | 14 |
| 31 Dec 17 | 72 | -31 | 55 | 0 |
| 30 Sep 17 | 71 | -27 | 53 | 14 |
| 30 Jun 17 | 72 | -26 | 52 | 15 |
| 31 Mar 17 | 68 | -29 | 52 | 16 |
| 31 Dec 16 | 65 | -31 | 52 | 15 |
| 30 Sep 16 | 61 | -35 | 53 | 15 |
| 30 Jun 16 | 55 | -38 | 52 | 15 |
| 31 Mar 16 | 52 | -36 | 50 | 13 |
| 31 Dec 15 | 50 | -34 | 48 | 13 |
| 30 Sep 15 | 48 | -34 | 48 | 13 |
| 30 Jun 15 | 45 | -33 | 47 | 11 |
質の高い収益: VCYTは 高品質の収益 を持っています。
利益率の向上: VCYTの現在の純利益率 (16.2%)は、昨年(7.1%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: VCYT過去 5 年間で収益を上げており、収益は年間53.1%増加しています。
成長の加速: VCYTの過去 1 年間の収益成長率 ( 166.3% ) は、5 年間の平均 ( 年間53.1%を上回っています。
収益対業界: VCYTの過去 1 年間の収益成長率 ( 166.3% ) はBiotechs業界43%を上回りました。
株主資本利益率
高いROE: VCYTの 自己資本利益率 ( 6.5% ) は 低い とみなされます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 17:51 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Veracyte, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24
| アナリスト | 機関 |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |